{"groups":[{"description":"Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).","id":"FG000","title":"Low Dose Escalation Cohort: Crizotinib 50 mg QD"},{"description":"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"FG001","title":"Low Dose Escalation Cohort: Crizotinib 100 mg QD"},{"description":"Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).","id":"FG002","title":"Low Dose Escalation Cohort: Crizotinib 200 mg QD"},{"description":"Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).","id":"FG003","title":"Low Dose Escalation Cohort: Crizotinib 200 mg BID"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).","id":"FG004","title":"Low Dose Escalation Cohort: Crizotinib 250 mg BID"},{"description":"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"FG005","title":"Low Dose Escalation Cohort: Crizotinib 300 mg BID"},{"description":"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).","id":"FG006","title":"High Dose Escalation Cohort: Crizotinib 300 mg QD"},{"description":"Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).","id":"FG007","title":"High Dose Escalation Cohort: Crizotinib 400 mg QD"},{"description":"Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).","id":"FG008","title":"High Dose Escalation Cohort: Crizotinib 500 mg QD"},{"description":"Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).","id":"FG009","title":"High Dose Escalation Cohort: Crizotinib 650 mg QD"},{"description":"Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).","id":"FG010","title":"High Dose Escalation Cohort: Crizotinib 800 mg QD"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"FG011","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"FG012","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"FG013","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).","id":"FG014","title":"RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).","id":"FG015","title":"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"FG016","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).","id":"FG017","title":"RP2D Cohort: Enriched Other: Crizotinib 250 mg"},{"description":"Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.","id":"FG018","title":"RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.","id":"FG019","title":"RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin"},{"description":"Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1","id":"FG020","title":"RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"8"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"4"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"14"},{"groupId":"FG017","numSubjects":"9"},{"groupId":"FG018","numSubjects":"2"},{"groupId":"FG019","numSubjects":"3"},{"groupId":"FG020","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"25"},{"groupId":"FG012","numSubjects":"29"},{"groupId":"FG013","numSubjects":"26"},{"groupId":"FG014","numSubjects":"21"},{"groupId":"FG015","numSubjects":"12"},{"groupId":"FG016","numSubjects":"94"},{"groupId":"FG017","numSubjects":"42"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"9"},{"groupId":"FG020","numSubjects":"8"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"8"},{"groupId":"FG012","numSubjects":"15"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"3"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"7"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"2"},{"groupId":"FG019","numSubjects":"2"},{"groupId":"FG020","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"19"},{"groupId":"FG012","numSubjects":"24"},{"groupId":"FG013","numSubjects":"7"},{"groupId":"FG014","numSubjects":"11"},{"groupId":"FG015","numSubjects":"3"},{"groupId":"FG016","numSubjects":"28"},{"groupId":"FG017","numSubjects":"12"},{"groupId":"FG018","numSubjects":"10"},{"groupId":"FG019","numSubjects":"4"},{"groupId":"FG020","numSubjects":"2"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"3"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"2"}],"type":"Randomized not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"7"},{"groupId":"FG013","numSubjects":"2"},{"groupId":"FG014","numSubjects":"8"},{"groupId":"FG015","numSubjects":"2"},{"groupId":"FG016","numSubjects":"11"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Site Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"Withdrawn Due to Pregnancy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"11"},{"groupId":"FG011","numSubjects":"53"},{"groupId":"FG012","numSubjects":"85"},{"groupId":"FG013","numSubjects":"41"},{"groupId":"FG014","numSubjects":"48"},{"groupId":"FG015","numSubjects":"19"},{"groupId":"FG016","numSubjects":"154"},{"groupId":"FG017","numSubjects":"67"},{"groupId":"FG018","numSubjects":"21"},{"groupId":"FG019","numSubjects":"18"},{"groupId":"FG020","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"9"},{"groupId":"FG011","numSubjects":"53"},{"groupId":"FG012","numSubjects":"85"},{"groupId":"FG013","numSubjects":"41"},{"groupId":"FG014","numSubjects":"48"},{"groupId":"FG015","numSubjects":"18"},{"groupId":"FG016","numSubjects":"154"},{"groupId":"FG017","numSubjects":"66"},{"groupId":"FG018","numSubjects":"18"},{"groupId":"FG019","numSubjects":"18"},{"groupId":"FG020","numSubjects":"12"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"11"},{"groupId":"FG011","numSubjects":"53"},{"groupId":"FG012","numSubjects":"85"},{"groupId":"FG013","numSubjects":"41"},{"groupId":"FG014","numSubjects":"48"},{"groupId":"FG015","numSubjects":"19"},{"groupId":"FG016","numSubjects":"154"},{"groupId":"FG017","numSubjects":"67"},{"groupId":"FG018","numSubjects":"21"},{"groupId":"FG019","numSubjects":"18"},{"groupId":"FG020","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"There was a lead-in period of 7 days in which single-dose pharmacokinetics of crizotinib or midazolam was characterized on Day-7, prior to initiation of continuous dosing in the first cycle (each cycle 28 days) of treatment in dose escalation cohorts and recommended phase 2 dose (RP2D) cohorts."}